Literature DB >> 19536905

Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation.

Stephanie Campbell1, Can-Lan Sun, Seira Kurian, Liton Francisco, Andrea Carter, Sameer Kulkarni, Pablo Parker, Chatchada Karanes, Stephen J Forman, Smita Bhatia.   

Abstract

BACKGROUND: Avascular necrosis (AVN) is a debilitating condition reported after chronic steroid use. The purpose of this study was to describe the magnitude of risk in individuals who survived >or=1 years after hematopoietic cell transplantation (HCT), and to investigate the role of immunosuppressive agents such as prednisone, tacrolimus (FK506), mycophenolate mofetil (MMF), and cyclosporine (CSA) in the development of AVN after HCT.
METHODS: Using a retrospective study design, the authors followed 1346 eligible patients for the development of AVN. Cumulative incidence was calculated taking into consideration competing risk from death and disease recurrence. Cox proportional regression techniques were used to identify associated risk factors.
RESULTS: The median age at HCT was 34 years (range, 7 months-69 years), and median length of follow-up for those surviving was 8.2 years. Seventy-five patients developed AVN of 160 joints. The cumulative incidence of AVN at 10 years was 2.9% after autologous HCT, 5.4% after allogeneic matched related donor HCT, and 15% after unrelated donor HCT (P<.001 compared with autologous HCT recipients). For allogeneic transplant recipients, male sex (relative risk [RR], 2.1; 95% confidence interval [95% CI], 1.1-4.0); presence of chronic graft-versus-host disease (RR, 2.2); and exposure to CSA, FK506, prednisone, and MMF rendered patients at increased risk, especially in patients with a history of exposure to >or=3 drugs (RR, 9.2; 95% CI, 2.42-35.24).
CONCLUSIONS: Future studies examining the pathogenetic mechanism underlying AVN should help develop targeted interventions to prevent this chronic debilitating condition. Copyright (c) 2009 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19536905      PMCID: PMC2741534          DOI: 10.1002/cncr.24474

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

1.  Risk factors for avascular bone necrosis after renal transplantation.

Authors:  S Tang; T M Chan; S L Lui; F K Li; W K Lo; K N Lai
Journal:  Transplant Proc       Date:  2000-11       Impact factor: 1.066

2.  Osteonecrosis of the femoral head after allogeneic bone marrow transplantation.

Authors:  Y Torii; Y Hasegawa; T Kubo; Y Kodera; S Minami; Y Morishita; Y Yamada; H Iwata
Journal:  Clin Orthop Relat Res       Date:  2001-01       Impact factor: 4.176

3.  Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study.

Authors:  J M Stern; K M Sullivan; S M Ott; K Seidel; J C Fink; G Longton; D J Sherrard
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

4.  Bony morbidity in children treated for acute lymphoblastic leukemia.

Authors:  A J Strauss; J T Su; V M Dalton; R D Gelber; S E Sallan; L B Silverman
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

Review 5.  Pathogenesis and natural history of osteonecrosis.

Authors:  Yehudith Assouline-Dayan; Christopher Chang; Adam Greenspan; Yehuda Shoenfeld; M Eric Gershwin
Journal:  Semin Arthritis Rheum       Date:  2002-10       Impact factor: 5.532

6.  Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.

Authors:  L A Mattano; H N Sather; M E Trigg; J B Nachman
Journal:  J Clin Oncol       Date:  2000-09-15       Impact factor: 44.544

7.  Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  G Socié; P Loiseau; R Tamouza; A Janin; M Busson; E Gluckman; D Charron
Journal:  Transplantation       Date:  2001-08-27       Impact factor: 4.939

8.  Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review.

Authors:  Libuse Tauchmanovà; Gennaro De Rosa; Bianca Serio; Flavio Fazioli; Ciro Mainolfi; Gaetano Lombardi; Annamaria Colao; Marco Salvatore; Bruno Rotoli; Carmine Selleri
Journal:  Cancer       Date:  2003-05-15       Impact factor: 6.860

Review 9.  Osteonecrosis: current perspectives on pathogenesis and treatment.

Authors:  C C Chang; A Greenspan; M E Gershwin
Journal:  Semin Arthritis Rheum       Date:  1993-08       Impact factor: 5.532

10.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.

Authors:  Sibel Koc; Wendy Leisenring; Mary E D Flowers; Claudio Anasetti; H Joachim Deeg; Richard A Nash; Jean E Sanders; Robert P Witherspoon; Rainer Storb; Frederick R Appelbaum; Paul J Martin
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

View more
  24 in total

Review 1.  Musculoskeletal pain associated with corticosteroid therapy in cancer.

Authors:  Deborah A Frieze
Journal:  Curr Pain Headache Rep       Date:  2010-08

2.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

3.  Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS).

Authors:  Can-Lan Sun; Liton Francisco; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

Review 4.  Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up.

Authors:  Smita Bhatia
Journal:  Expert Rev Hematol       Date:  2011-08       Impact factor: 2.929

Review 5.  Survivorship after allogeneic transplantation-management recommendations for the primary care provider.

Authors:  André Tichelli; Alicia Rovó
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

6.  Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning.

Authors:  Johanna Konopacki; Raphaël Porcher; Marie Robin; Sabine Bieri; Jean-Michel Cayuela; Jérôme Larghero; Aliénor Xhaard; Anna Lisa Andreoli; Nathalie Dhedin; Anna Petropoulou; Paula Rodriguez-Otero; Patricia Ribaud; Hélène Moins-Teisserenc; Maryvonnick Carmagnat; Antoine Toubert; Yves Chalandon; Gérard Socie; Régis Peffault de Latour
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

7.  Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS).

Authors:  Saro H Armenian; Can-Lan Sun; Toana Kawashima; Mukta Arora; Wendy Leisenring; Charles A Sklar; K Scott Baker; Liton Francisco; Jennifer Berano Teh; George Mills; F Lennie Wong; Joseph Rosenthal; Lisa R Diller; Melissa M Hudson; Kevin C Oeffinger; Stephen J Forman; Leslie L Robison; Smita Bhatia
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

8.  Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents.

Authors:  Xiaxin Li; Ruta Brazauskas; Zhiwei Wang; Amal Al-Seraihy; K Scott Baker; Jean-Yves Cahn; Haydar A Frangoul; James L Gajewski; Gregory A Hale; Jack W Hsu; Rammurti T Kamble; Hillard M Lazarus; David I Marks; Richard T Maziarz; Bipin N Savani; Ami J Shah; Nirali Shah; Mohamed L Sorror; William A Wood; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-02       Impact factor: 5.742

9.  How I treat late effects in adults after allogeneic stem cell transplantation.

Authors:  Bipin N Savani; Michelle L Griffith; Shubhada Jagasia; Stephanie J Lee
Journal:  Blood       Date:  2010-12-30       Impact factor: 22.113

Review 10.  Pain in cancer survivors.

Authors:  Paul A Glare; Pamela S Davies; Esmé Finlay; Amitabh Gulati; Dawn Lemanne; Natalie Moryl; Kevin C Oeffinger; Judith A Paice; Michael D Stubblefield; Karen L Syrjala
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.